| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8313872 | Clinica Chimica Acta | 2013 | 5 Pages |
Abstract
⺠NAT2, CYP2E1 and GSTM1/GSTT1 variants influence safety of anti-tuberculosis therapy. ⺠NAT2*5/*5 carriers have increased susceptibility to mild elevation in liver enzymes. ⺠CYP2E1 and GSTM1/GSTT1 are common variants that are related to increased liver biomarkers. ⺠CYP2E1 inhibitors increase the susceptibility to increased liver biomarkers in TB.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Francisco Jose Forestiero, Leticia Cecon, Mario Hirouki Hirata, Fernando Fiuza de Melo, Rosilene Fressatti Cardoso, Alvaro Cerda, Rosario Dominguez Crespo Hirata,